Trial Profile

An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE)

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brazikumab (Primary) ; Brazikumab (Primary)
Indications Crohn's disease
Focus Adverse reactions
Acronyms Intrepid; INTREPID OLE
Sponsors AbbVie; Allergan; AstraZeneca; AstraZeneca AB

Most Recent Events

24 Nov 2023 The trial has been completed in Germany (End Date: 19 Sep 2023), according to European Clinical Trials Database record.
19 Oct 2023 Status changed from active, no longer recruiting to discontinued.
06 Sep 2023 This trial has been discontinued in Spain (Global end date: 1 June 2023).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com